What is JNJ stock price target for 2026?

WallStSmart's 12-month price target for Johnson & Johnson is $299.87, representing 30.5% upside from the current price of $229.85.

What is JNJ stock forecast?

Johnson & Johnson forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is JNJ undervalued based on price targets?

Our DCF intrinsic value for Johnson & Johnson is $160.13, against a current price of $229.85. The margin of safety is -41.97%.

JNJ

Johnson & Johnson

NYSE: JNJ · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$229.85

+1.10% today

Updated 2026-04-29

Market cap

$547.64B

P/E ratio

26.39

P/S ratio

5.68x

EPS (TTM)

$8.62

Dividend yield

2.25%

52W range

$142 – $252

Volume

8.0M

Market cap

$547.64B

P/E ratio

26.39

P/S ratio

5.68x

EPS (TTM)

$8.62

Dividend yield

2.25%

52W range

$142 – $252

Volume

8.0M

Johnson & Johnson (JNJ) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$229.85

Consensus

$238,200.00

+103532.80%

2030 Target

$203.49

-11.47%

DCF

$160.13

-41.97% MoS

Current price

$229.85

Analyst consensus

$238,200.00

+103532.80%

2030 Target

$203.49

-11.47%

Intrinsic (DCF)

$160.13

-41.97% MoS

20 analysts:

12 Buy8 Hold1 Sell

Management guidance

JNJ raised 2026 full-year guidance following strong Q1 2026 results. Company projects revenue to exceed $100B in 2026 (raised from prior guidance). Management indicated oncology-driven growth momentum with multiple drug approvals (Icotyde, Rybrevant) and pipeline catalysts including Ottava robotic surgery system pending FDA approval.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$339.15

$130.5B Rev × 6.4x P/S

Base case (2030)

$203.49

$130.5B Rev × 4x P/S

Bear case (2030)

$135.66

$130.5B Rev × 2.4x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$85.2B	$88.8B	$94.2B	$102.3B	$109.9B	$117.2B	$124.1B	$130.5B
Revenue growth	—	4.3%	6.0%	8.6%	7.4%	6.6%	5.9%	5.1%
EPS	$10.43	$9.99	$10.80	$11.80	$12.65	$13.45	$14.20	$14.85
P/S ratio	—	—	—	4.0x	4.0x	4.0x	4.0x	4.0x
Implied price	—	—	—	$158.27	$180.88	$180.88	$203.49	$203.49

Catalysts & risks

Growth catalysts

+ Ottava robotic surgery system FDA approval (near-term)

+ JNJ-78934804 autoimmune/gut health therapy clinical trial outcomes

+ Oncology pipeline momentum (Icotyde, Rybrevant post-approval uptake)

+ ETHICON 4000 Stapler European integration with OTTAVA platform

+ Talc litigation resolution and liability tail reduction

Key risks

- Ongoing talc litigation creating earnings volatility and balance sheet drag

- Patent expirations on key legacy franchises (broader pharma risk)

- Regulatory delays on Ottava or other pipeline assets

- Pricing pressure in healthcare and increased generics competition

- Macroeconomic headwinds impacting elective medical device procedures

Methodology

Johnson & Johnson's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 20 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 23, 2026.